Black Diamond Therapeutics

Black Diamond Therapeutics is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts. The company employs 69 people. Black Diamond Therapeutics is focused on developing MasterKey therapies that target families of oncogenic mutations. Their mission is to provide people living with cancer the opportunity to experience longer, healthier, and more active lives. The company is advancing two clinical-stage programs: BDTX-1533, a fourth-generation EGFR inhibitor targeting non-small cell lung cancer (NSCLC) and glioblastoma (GBM), and BDTX-4933, a RAF inhibitor targeting KRAS, NRAS, and BRAF alterations in NSCLC and other solid tumors. Black Diamond Therapeutics differentiates itself through its MasterKey platform, which allows for the development of therapies that target multiple mutations within a specific family. This approach has the potential to overcome resistance to existing cancer treatments and provide more durable responses. For more information about Black Diamond Therapeutics, please visit their website at blackdiamondtherapeutics.com.